menu
    • menu
    [{"orgOrder":0,"company":"ATB Therapeutics","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Atbody-st-2","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ATB Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATB Therapeutics \/ ATB Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"ATB Therapeutics \/ ATB Therapeutics"},{"orgOrder":0,"company":"ATB Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ATB Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"ATB Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"ATB Therapeutics \/ EQT Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by ATB Therapeutics

    Menu

    ATB Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ATB Therapeutics

                            Belgium arrow
                            CTAD25
                            Not Confirmed

                            ATB Therapeutics

                            Belgium arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : EQT Life Sciences

                            Deal Size : $56.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            EQT Life Sciences Leads €54 Million Series A Financing of ATB Therapeutics

                            Details : The proceeds will fund development of oncology and immunology therapeutics derived from innovative antibody payload platform, including novel antibody therapies for oncology and auto-immune disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : EQT Life Sciences

                            Deal Size : $56.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ATB Therapeutics

                            Belgium arrow
                            CTAD25
                            Not Confirmed

                            ATB Therapeutics

                            Belgium arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atbody-st-2

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : iBio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

                            Details : iBio has entered into its first Statement of Work under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 01, 2020

                            Lead Product(s) : Atbody-st-2

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : iBio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth